Ginsenoside Rb1 has been demonstrated to protect dopaminergic (DA) neurons from death in vitro. However, the neuroprotective effects and underlying mechanism of Rb1 in treating Parkinson's disease (PD) remain uncharacterized. In this study, we explored the effects of Rb1 on the movement disorder and the underlying mechanisms based on the glutamatergic transmission and excitotoxicity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Here, for the first time, we report that Rb1 treatment ameliorates motor deficits, prevents DA neuron death, and suppresses a-synuclein expression and astrogliosis in the MPTP mouse model of PD. Rb1 attenuates glutamate excitotoxicity by upregulating glutamate transporter expression and function, and modulating the nigrostriatal and cortico-nigral glutamatergic transmission pathways. Our results demonstrate that Rb1 increases glutamate transporter expression via nuclear translocation of nuclear factor-kappa B, regulates glutamate receptor expression and promotes synaptic protein expression. These results indicate that Rb1 suppresses glutamate excitotoxicity and modulates synaptic transmission to improve the impairments in motor functions of the MPTP model of PD, suggesting that Rb1 may serve as a potential therapeutic agent for PD.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder that is classically characterized by motor symptoms associated with dopaminergic (DA) neuron loss in the nigrostriatal pathway (Samii et al., 2004) . In addition to motor impairments, progressive cognitive, emotional and olfactory symptoms are frequently observed in patients with PD (Braak et al., 2003; Pedersen et al., 2017) . PD animal models can be generated by the administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Within these models, MPTP model is an commonly used experimental model of PD which by selectively damaging the dopaminergic nigrostriatal system through mitochondrial dysfunction, glutamate excitotoxicity and oxidative stress (Beal, 1998; Bisht et al., 2014; Selvakumar et al., 2015) .
Glutamate excitotoxicity has been proposed as an important accelerator of DA neuron degeneration in the pathogenesis of PD Sonsalla et al., 1998) . Excessive glutamate in the synaptic cleft is normally taken up by excitatory amino acid transporters (EAATs), which include the glutamate/aspartate transporter (GLAST, also called EAAT1), glutamate transporter-1 (GLT-1), excitatory amino acid carrier-1 (EAAC1, also called EAAT3), EAAT4 and EAAT5 (Arriza et al., 1994 (Arriza et al., , 1997 Fairman et al., 1995; Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992) .
Abbreviations: EAAC1, excitatory amino acid carrier-1; EAATs, excitatory amino acid transporters; GLAST, glutamate/aspartate transporter; GLT-1, glutamate transporter-1; mEPSCs, miniature excitatory postsynaptic currents; MPP þ , 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-kB, nuclear factor-kappa B; PFC, prefrontal cortex; SNpc, pars compacta of the substantia nigra; SNpr, pars reticulate of the substantia nigra; TH, tyrosine hydroxylase.
Astrocytic GLT-1 is responsible for clearing nearly 90% of the glutamate in the central nervous system . Previous studies indicate that dysfunction of glutamate transporters in the glutamatergic excitatory system contribute to the motor disorder in PD, while restoration of glutamate transporters by administration of ceftriaxone, rapamycin or iptakalim has beneficial effects (Aoyama et al., 2008; Assous et al., 2014; Chung et al., 2008; Rothstein et al., 2005; Salvatore et al., 2012; Sun et al., 2008; Zhang et al., 2015 Zhang et al., , 2017a . Thus, glutamate transporters are potential therapeutic targets for treating PD by terminating excessive glutamate transmission.
Ginseng, the root of Panax ginseng C.A. Meyer (Araliaceae), is considered to be the most precious herbal medicine and is widely used in the Far East. The main active ingredient of P. ginseng, Ginsenoside Rb1, has been proposed to be neuroprotective against several central nervous system diseases. Rb1 can protect DA neurons, SH-SY5Y cells and PC12 cells from 6-OHDA or 1-methyl-4-phenylpyridinium-iodide (MPP þ ) toxicity (Ahmed et al., 2016; Gonzalez-Burgos et al., 2015; Radad et al., 2004) . Furthermore, Rb1 can suppress the fibrillation and toxicity of a-synuclein, disaggregate preformed fibrils and inhibit the polymerization of asynuclein in vitro (Ardah et al., 2015) . However, the neuroprotective effects and regulatory mechanisms of Rb1 in PD animal models remain undetermined.
In this study, we provide evidence that Rb1 ameliorates the motor disorder in a PD animal model. For the first time, we reveal the neuroprotective mechanisms of Rb1 in the MPTP mouse model involve the upregulation of glutamate transporter GLT-1 to terminate glutamate excitotoxicity in the nigrostriatal and corticonigral systems. These findings expand our understanding of the pharmacological effects and neuroprotective mechanisms of Rb1 in PD.
Material and methods

Reagents
MPP
þ and MPTP were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ginsenoside Rb1 was purchased from MUST Biotechnology (Chengdu, China). Dulbecco's modified Eagle's medium/F12 (DMEM/F12) and fetal calf serum were purchased from Hyclone (Logan, UT, USA). L-[ 3 H]-Glutamic acid was purchased from PerkinElmer (Boston, MA). Anti-GLT-1, anti-GLAST and anti-EAAC1 antibodies were purchased from Proteintech (Rosemont, IL, USA). Anti-TH, anti-a-synuclein, anti-DAT, anti-GFAP and anti-Integrin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-NR1, anti-synaptophysin and anti-PSD-95 antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-NR2B were purchased from Millipore (Bedford, MA, USA). Anti-phospho-PI3K p85-a (Tyr607), anti-PI3K p85-a, antiphospho-Akt (Ser473), anti-Akt, anti-phospho-NF-kB p65 (Ser276), anti-NF-kB p65, anti-GluR1, anti-GluR2 and anti-H3 antibodies were purchased from EnoGene (Nanjing, China). Anti-actin antibody, Nuclear and Cytoplasmic Protein Extraction Kits, TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) Staining Assay Kits and Cell counting kit-8 (CCK-8) were purchased from Beyotime (Shanghai, China). NF-kB inhibitor (BAY 11e7082) was purchased from Selleck Chemicals (Houston, TX, USA). Anti-Alexa Fluor 488-conjugated goat anti-mouse, anti-Alexa Fluor 594-conjugated goat anti-rabbit, horseradish peroxidaseconjugated goat anti-mouse, and rabbit antibodies were purchased from Boster (Wuhan, China). EZ-Link Sulfo-NHS-SS-Biotin was purchased from Thermo Scientific (Waltham, MA, USA; no. 21331). Trizol was purchased from Invitrogen (Carlsbad, CA, USA). PrimeScript RT Reagent Kits and SYBR Premix Ex Taq Kits were purchased from Takara (Otsu, Japan).
Animals and cell culture
Ten-week-old, C57BL/6 male mice were obtained from the SLAC Laboratory Animal Co., Ltd (Shanghai, China). Primary cortical astrocytes were obtained from newborn C57BL/6 mice and were cultured in DMEM/F12 supplemented with 10% fetal calf serum as described previously (Zhang et al., , 2017a . All animal protocols in this study were approved by the Institutional Animal Care and Use Committee of Xiamen University.
Drug treatment
Stock solutions of MPP þ and Rb1 were prepared in 0.01 M phosphate-buffered saline (PBS) and diluted to the appropriate concentrations using cell culture medium. The working concentration of MPP þ for astrocytes was 1000 mM, as described by our work and the work of others (Sundar Boyalla et al., 2011; Zhang et al., 2015) . Rb1 was dissolved with vehicles and diluted to the test concentration before experiments. For in vitro assays, cells were randomly divided into four groups and treated for 24 h: (1) Control group: Cells were treated with normal culture medium; (2) MPP þ group: Cells were treated with culture medium containing 1000 mM MPP þ ; (3) MPP þ þRb1 group: Cells were treated with culture medium containing 1000 mM MPP þ and various final concentrations of Rb1; (4) Rb1 group: Cells were treated with culture medium containing various concentrations of Rb1. To explore the effects of different concentrations and timepoints of Rb1 treatment on in vivo glutamate transporter expression, mice were intraperitoneally or intragastrically administered with 10, 20 or 40 mg/kg of Rb1. After 48 h, the midbrain and prefrontal cortex (PFC) were separated and glutamate transporter expression was examined. Alternatively, mice were intraperitoneally or intragastrically administered with 40 mg/kg of Rb1, the midbrain and PFC was separated after 2 h, 8 h, 24 h and 48 h, and glutamate transporter expression was examined.
To explore the neuroprotective effects of Rb1 in vivo, PD model animals were generated by administration of MPTP intraperitoneally for 5 consecutive days at a dose of 30 mg/kg free base (MPTPHCl) in saline (Jackson-Lewis and Przedborski, 2007; Zhang et al., 2017a) . The vehicle for Rb1 was also saline. Rb1 or saline was administered intraperitoneally for 14 consecutive days, starting 3 days before MPTP treatment, at a dose of 10 or 40 mg/kg. The time interval between MPTP and Rb1 injections was more than 12 h. One day after the last Rb1/saline injection, behavioral tests were performed and the animals were sacrificed by isoflurane anesthesia for tissue collection and electrophysiological recording.
Behavioral tests
Grasping test
According to previous studies, mice were subjected to the grasping experiment at the 6th day after the last MPTP injection (Leung et al., 2012; Zhang et al., 2017a) .
Pole-climbing test
The pole-climbing test was performed as described previously (Liu et al., 2012b; Zhang et al., 2017a) .
Rotarod test
As described previously (Guo et al., 2016) , mice were tested with the rotarod experiment at the 6th day after the last MPTP injection. The mice were trained twice a day for 2 successive days, and then on the third day they were placed on the rotating bar of a rotarod unit (DXP-2; Institute of Materia Medica, Chinese Academy of Medical Sciences) at a rotation speed of 25 rpm. The latent period was recorded as the time spent on the rotating bar.
Tissue preparation
Mice were perfused after behavioral tests to obtain brain sections. For protein expression, mRNA expression and glutamate uptake assessments, mice were anesthetized and perfused transcardially with 0.9% saline to remove traces of blood. The midbrain, striatum and PFC tissues were removed and stored at À80 C. For the morphological experiments, the mice were anesthetized and perfused transaortally with 0.9% saline followed by fixative (4% paraformaldehyde in 0.01 M PBS, pH 7.4). Then, the fixed brains were removed, stored overnight at 4 C in postfix solution (4% paraformaldehyde in 0.01 M PBS, pH 7.4), and dehydrated in a gradient of 20e30% sucrose. The embedded brains were cut into sections of 15 mm with a freezing microtome (Leica, Germany), which were subsequently stored at À80 C before use.
L-[
3 H]-glutamic acid uptake assay L-[ 3 H]-Glutamic acid uptake assays were performed as described previously (Zhang et al., , 2017a . Astrocytes were incubated with choline solution (150 mM choline chloride, 5 mM KP i , pH 7.4, 0.5 mM MgSO 4 and 0.3 mM CaCl 2 ) containing 0.4 mCi L-
]-Glutamic acid (specific activity 12.9 Ci/mmol) at room temperature for 10 min, and the reactions were terminated by washing twice in ice-cold NaCl solution (150 mM NaCl, 5 mM KP i , pH 7.4, 0.5 mM MgSO 4 and 0.3 mM CaCl 2 ). The radioactivity was measured by liquid scintillation counting. Data are from three separate experiments performed in triplicate.
Determination of glutamate uptake in the synaptosomes
Glutamate uptake in the synaptosomes of the midbrain and striatum was assessed as previously described (Zhang et al., 2017a) . Briefly, brain tissues were homogenized in 0.32 M sucrose solution (0.32 M sucrose, 5 mM Hepes, pH 7.4) and centrifuged to obtain the crude synaptosomes. Then the crude synaptosomes were incubated with 1 mCi L-[ 3 H]-glutamic acid at 25 C for 10 min following resuspension in Kreb's buffer (127 mM NaCl, 3.73 mM KCl, 1.8 mM CaCl 2 , 1.18 mM KH 2 PO 4 , 20 mM NaHCO 3 , 2 mM ATP, 2 g/l D-glucose, pH 7.4). The uptake assay was terminated by using ice-cold Kreb's buffer. Finally, the radioactivity in the filtered synaptosomes was assessed by liquid scintillation counting. Data are from three separate experiments performed in triplicate and are expressed as cpm/mg protein/min.
Cell viability assay
A cell counting kit-8 (CCK-8) was used to measure astrocyte viability as reported previously . Briefly, 1 Â 10 4 cells were seeded into 96-well plates, and treated with different concentration of Rb1 or MPP þ . Then the culture medium was removed and plates were washed twice with PBS. Serum-free DMEM/F12 medium and CCK-8 solutions were added into each well. After being incubated at 37 C for 1 h, the absorbance at 450 nm was measured in a microplate reader (PerkinElmer, USA).
Immunohistochemistry assay
Immunohistochemical staining was performed as described previously (Zhang et al., 2017a) . Briefly, the slices were permeabilized with 0.3% Triton X-100 and 3% H 2 O 2 solution for 10 min. The slices were blocked with 5% bovine serum albumin (BSA) to prevent nonspecific staining and then incubated overnight at 4 C with primary antibody in 5% BSA. After being washed with PBS, the slices were incubated with biotinylated secondary antibodies at 37 C for 2 h. The sections were visualized by diaminobenzidine (DAB, Boster, Wuhan, China) reaction. Total numbers of TH-positive neurons in SNpc in Fig. 4E were counted stereologically using the optical fractionator method (Liberatore et al., 1999) . Briefly, THpositive neurons were counted in the right and left SNpc of each section throughout the entire extent of the SNpc. Each midbrain section was viewed at low power ( Â 10 objective), and the SNpc was outlined by using the set of anatomical landmarks. Then at a random start, the number of TH-positive cells were counted at high power ( Â 400). TH-positive cells were counted only when their nuclei were optimally visualized, which occurred only in one focal plane. Striatal OD of TH immunostaining in Supplementary Fig. 2C determined by the Image-Pro Plus 6.0 photogram analysis system (IPP 6.0, Media Cybernetics, Bethesda, MD), was used as an index of striatal density of TH innervation (Teismann et al., 2003) . THpositive neurons number and integrated OD was assessed at 400 Â magnification in at least 10 high-power fields from brain sections of representative mice in each group.
Immunocytochemistry
Immunocytochemical staining was performed as described previously . Astrocytes were seeded on glass bottom cell culture dishes (NEST, Shanghai, China). After fixation in 4% paraformaldehyde, astrocytes were permeabilized with 0.1% Triton X-100 and blocked with 5% BSA. Then, cells were incubated with primary antibodies against GLT-1 and NF-kB overnight at 4 C. After the incubation, astrocytes were washed with PBS and incubated with Alexa Fluor 488 and Alexa Fluor 594-conjugated secondary antibodies at 37 C for 1 h. DAPI was used to stain cell nuclei. Immunostaining was then examined by using the Olympus 1 Â 81 FV1000 Laser Scanning Confocal Microscope (Shinjuku, Tokyo, Japan).
Quantitative real-time (RT)-PCR
GLT-1 and GLAST mRNA expression was verified by qRT-PCR following published procedures (Zhang et al., 2017a) . Specifically, RNA was isolated and purified from astrocytes using Trizol. After reverse transcription to synthesize first-strand cDNA, the cDNA was quantified using the SYBR Premix Ex Taq kit. RNA levels were quantified with the DDCt method and Actin as a normalization control, and all analyses were performed in triplicate. All primers were previously validated: GLT-1 (forward) 5 0 -CGATGAGCCAAAG-CACCGAA-3 0 and (reverse) 5 0 -CTGGAGATGATAAGAGGGAGGATG-3 0 ; GLAST (forward) 5 0 -TCAAGTTCTGCCACCCTACC-3 0 and (reverse) 5 0 -TCTGTCCAAAGTTCAGGTCAA-3 0 ; b-actin (forward) 5 0 -CTA-CAATGAGCTGCGTGTGGC-3 0 and (reverse) CAGGTCCA-GACGCAGGATGGC (Zhang et al., 2017a) .
Total protein extraction
Cells or brain tissues were homogenized in lysis buffer (Beyotime, Shanghai, China) containing 1 mM PMSF, and the protein concentrations were determined by BCA assay (Beyotime, Shanghai, China). Protein samples were diluted with loading buffer and heated at 95 C for 5 min.
Cell surface biotinylation
Cell surface protein expression was determined using the membrane-impermeable biotinylation reagent EZ-Link Sulfo-NHS-SS-Biotin, as described previously (Zhang et al., 2017a) . Briefly, cells or tissues were washed twice with ice-cold PBS and then incubated with 2.5 ml EZ-Link Sulfo-NHS-SS-Biotin (0.5 mg/ml; dissolved in PBS) at 4 C for two successive rounds of 20 min. Afterwards, excess biotin was quenched with 100 mM glycine, and then cells or homogenized tissues were incubated for 20 min in lysis buffer containing protease inhibitor mixture and 1 mM PMSF. Biotinylated proteins were precipitated using agarose-conjugated streptavidin, and bound proteins were re-solubilized and denatured using loading buffer (Beyotime, Shanghai, China). The member protein samples were analyzed by SDS-PAGE.
Nuclear and cytoplasmic protein extraction
The nuclear and cytoplasmic proteins in midbrain tissues were extracted according to Beyotime's instructions. Brain tissues were homogenized with 100 ml cytoplasmic protein extraction agent A and B supplemented with 1 mM PMSF at 4 C, and the homogenates were centrifuged at 1, 500 Â g at 4 C for 5 min. The pellets were dissolved in cytoplasmic protein extraction agent A, vortexed for 5 s, and incubated on ice for 15 min. Then, cytoplasmic protein extraction agent B was added, and the mixtures were incubated on ice for 1 min. The samples were then centrifuged for 5 min at 14, 000 Â g at 4 C, and the supernatants containing the cytosolic fractions were immediately frozen for further analysis. The pellets were resuspended in nuclear protein extraction agent supplemented with 1 mM PMSF. After 15 rounds of vortexing for 30 min and centrifuging at 14, 000 Â g at 4 C for 10 min, the supernatants containing the nuclear extracts were obtained and analyzed by SDS-PAGE.
Western blotting assay
Protein samples were resolved via 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. After blocking in 5% BSA for 2 h at room temperature, the membranes were incubated with primary antibody at 4 C overnight. Membranes were washed three times in TBS-T (Tris-buffered saline supplemented with 0.1% Tween 20) and incubated with secondary antibody at room temperature for 1 h. Subsequently, membranes were washed three additional times with TBST. Peroxidase activity was examined by enhanced chemiluminescence (Millipore, MA, USA) and chemiluminescent immunoreactive complexes were collected using the Tanon imager system (Shanghai, China). Protein levels were quantified using Image J software (NIH Image, Bethesda, MD). Actin or integrin immunoreactivity was set as control.
Brain slice preparation in electrophysiological experiments
The electrophysiological experiments were performed after the behavioral tests, and mice were anesthetized with isoflurane and quickly decapitated. Brains were rapidly removed and immersed in ice-cold oxygenated (95% O 2 e5% CO 2 ) sucrose artificial cerebrospinal fluid (ACSF) containing (in mM): sucrose (120), NaCl (64), KCl (2.5), NaH 2 PO 4 (1.25), NaHCO 3 (26), glucose (10), MgSO 4 (10), and CaCl 2 (0.5). Slices (350 mm) were prepared using a Vibratome (Leica 1000s, USA) and then incubated in normal ACSF containing (in mM): NaCl (126), KCl (2.5), NaH 2 PO 4 (1.25), NaHCO 3 (26), glucose (10), CaCl 2 (2), and MgSO 4 (2), with continuous bubbling with 95% O 2 e5% CO 2 at 32 C for 30 min and then incubated at room temperature. All experiments were performed within 1e8 h after slice preparation.
Whole-cell patch-clamp recording
Following incubation, slices were transferred to a recording chamber in which oxygenated ACSF was warmed to 32 C and superfused over the submerged slices at 2 ml/min. Recordings were collected from the PFC pyramidal neurons, with both miniature excitatory postsynaptic currents (mEPSCs) recorded at a holding potential of À65 mV. For mEPSCs recording, glass pipettes were filled with internal solution containing (in mM): K-gluconate (120), KCl (20) , HEPES (10), MgCl 2 (2), EGTA (0.1), sodium phosphocreatine (10), leupeptin (0.2), Mg-ATP (4), Na-GTP (0.3), and pH 7.3 (290 mOsm). GABA A receptors were pharmacologically blocked with 20 mM bicuculline, and tetrodotoxin (1 mM) was included in the perfusion solution for mEPSCs recording. Neurons were allowed to equilibrate for at least 5 min before recording. Data were acquired with a MultiClamp 700B (Molecular Devices, Sunnyvale, CA) at 10 kHz, filtered at 1 kHz, and stored for later analysis using pClamp software (Molecular Devices). Only recordings for which the access resistance changed <15% were retained for analysis. Mini events were analyzed with MiniAnalysis software (Synaptosoft, Inc.).
Statistics
Statistical analysis of data was performed by the Bonferroni post-hoc test based on the one-way or two-way analysis of variance (ANOVA) using SPSS 16.0 (SPSS Inc., Chicago, IL). The data are expressed as mean ± SEM, and statistical significance was set at p < .05.
Results
Ginsenoside Rb1 promotes GLT-1 expression via nuclear translocation of NF-kB in astrocytes
Glutamate excitotoxicity contributes to the pathogenesis of PD, and the glutamate transporters GLT-1 and GLAST are mainly expressed in astrocytes . Therefore, we examined the effects of Rb1 on glutamate transporter expression in astrocytes. Here, we reported that 10 and 50 mM Rb1 increased GLT-1 expression at the total protein level (p ¼ .021 and p ¼ .004, respectively, Bonferroni post-hoc test; one-way ANOVA, To explore the mechanism of Rb1 in regulating GLT-1 expression in astrocytes, we examined the PI3K/Akt/NF-kB signaling pathway, which has previously been shown to regulate GLT-1 expression (Feng et al., 2014; Zhang et al., 2013 Fig. 1D ), which suggests that PI3K/Akt signaling may be involved in Rb1 upregulation of GLT-1 expression. However, 1, 10 and 50 mM Rb1 showed no obvious effects on the astroglial viability (n.s., Bonferroni posthoc test; one-way ANOVA, F 3, 8 ¼ 21.164, p ¼ .341; Fig. 1E ).
As NF-kB is a canonical downstream signal of PI3K/Akt cascade, and NF-kB binds to the EAAT2/GLT-1 promoter and mediates its activation (Ghosh et al., 2011; Lee et al., 2008) . Therefore, we used the NF-kB inhibitor BAY 11e7082 to verify the role of NF-kB in Rb1 upregulation of GLT-1 expression. Using qRT-PCR, we verified that 10 and 50 mM Rb1 increased GLT-1 mRNA expression, and BAY 11e7082 counteracted the increased GLT-1 mRNA expression upon treatment of Rb1 (two-way ANOVA, for Rb1-treatment effect: F 3, 16 ¼ 32.256, p ¼ .036; for BAY 11-7082-treatment effect: F 3, 16 ¼ 26.659, p ¼ .022; Fig. 2A ). While Rb1 showed no obvious effects on GLAST mRNA expression at any of these tested concentrations (Fig. 2B) Fig. 2C ). These results suggest that Rb1 activation of GLT-1 expression is NF-kBdependent.
Generally, NF-kB is activated by proteasomal degradation of the cytoplasmic inhibitor IkB binding to the NF-kB complex, which releases NF-kB and translocates it from the cytoplasm to the nucleus and drive the expression of target genes (Karin, 2006) . Therefore, we examined the effects of Rb1 on NF-kB translocation by immunofluorescence double staining. Our results verify that Rb1 induces translocation of the p65 subunit of NF-kB to the nucleus and increases GLT-1 expression in the nucleus, whereas BAY 11e7082 inhibits the effect of Rb1 (Fig. 2D) .
To determine whether Rb1 has similar effects in MPP þ -treated astrocytes, we repeated the expression analyses using 50 mM Rb1, which showed the most consistent effects on GLT-1 expression and function in the absence of MPP þ treatment (Fig. 1AeC , and Fig. 2A ).
Rb1 increased GLT-1 expression in both vehicle (Con) and MPP þ -treated astrocytes at the total and membrane protein level but had no obvious effects on GLAST expression (total GLT-1 expression: Fig. 2G ). These results suggest that Rb1 promotes GLT-1 expression via nuclear translocation of NF-kB in astrocytes and suppresses potential excitotoxic damage (A and B) The effect of 1, 10 and 50 mM Rb1 on the expression of glutamate transporters at the total and membrane protein levels in astrocytes was determined by Western blotting. (C) The effect of 1, 10 and 50 mM Rb1 on glutamate uptake in astrocytes was determined by L-[ 3 H]-Glutamic acid uptake assay. (D) The effect of 1, 10 and 50 mM Rb1 on PI3K/Akt signaling in astrocytes was determined by Western blotting. (E) The effects of 1, 10 and 50 mM Rb1 on the astroglial viability was determined by CCK-8. Results are expressed as the mean ± SEM of three experiments, statistical significance was determined by one-way ANOVA and Bonferroni test as post-hoc comparisons.
* represents a significant difference as compared with the control (Con) or vehicle group, ** p < .01,
& represents a significant difference between 10 and 50 mM Rb1,
Intraperitoneal administration of Ginsenoside Rb1 promotes GLT-1 expression via nuclear translocation of NF-kB in the midbrain
To explore whether Rb1 also promotes glutamate transporter expression in vivo, we assessed the effects of intraperitoneal administration and intragastric administration of Rb1 on glutamate transporter expression in the midbrain. Intraperitoneal administration of 10, 20 and 40 mg/kg Rb1 increased GLT-1 expression in the midbrain but had no obvious influence on GLAST expression (GLT-1: p ¼ .000, Bonferroni post-hoc test; one-way ANOVA, F 3, 12 ¼ 499.710, p ¼ .000; GLAST: n.s., Bonferroni post-hoc test; oneway ANOVA, F 3, 12 ¼ 0.117, p ¼ .176; Fig. 3A) . Furthermore, the effects of intraperitoneal administration of 40 mg/kg Rb1 on GLT-1 expression were time-dependent, reaching a peak at 24 h and 48 h after administration, while Rb1 had no obvious influence on GLAST expression at these time points (GLT-1: p ¼ .000, Bonferroni post-hoc test; one-way ANOVA, F 4, 15 ¼ 315.620, p ¼ .000; GLAST: n.s., Bonferroni post-hoc test; one-way ANOVA, F 4, 15 ¼ 2.270, p ¼ .281; Fig. 3B ). Intragastric administration of 10, neither 20 nor 40 mg/kg Rb1 showed no obvious effects on GLT-1 or GLAST expression ( Supplementary Fig. 1A) , and 40 mg/kg Rb1 only increased GLT-1 expression at 24 h after Rb1 administration ( Supplementary Fig. 1B) .
To examine whether NF-kB regulates GLT-1 expression in vivo, we extracted the nuclear and cytoplasmic protein from midbrain tissue, and examined NF-kB expression. Intraperitoneal administration of 10, 20 and 40 mg/kg Rb1 increased the nuclear NF-kB expression and decreased the cytoplasmic NF-kB expression in a dose-dependent manner (nuclear NF-kB: p ¼ . Fig. 3C ). Furthermore, the effects of intraperitoneal administration of 40 mg/kg Rb1 in increasing * represents a significant difference as compared with the control or vehicle group, Fig. 3D ). These results suggest that intraperitoneal administration of Ginsenoside Rb1 promotes GLT-1 expression via nuclear translocation of NF-kB in vivo.
Ginsenoside Rb1 is neuroprotective in the MPTP model of PD
Ginsenoside Rb1 has been shown to protect against neuron death and inhibit fibrillation and toxicity of a-synuclein in vitro (Ahmed et al., 2016; Ardah et al., 2015; Gonzalez-Burgos et al., 2015; Radad et al., 2004) ; however, the effects of Rb1 in in vivo PD models remain underexplored. To explore the protective effects of Rb1 in the MPTP model, we assigned mice to four treatment groups: saline (Con), MPTP þ saline (MPTP), MPTP þ Rb1 10 mg/kg, and MPTP þ Rb1 40 mg/kg (Fig. 4A) Fig. 4E and F) . We also determine the number of non-TH labeled cells in each group and we found that there is no significant difference among these groups ( Supplementary Fig. 1C ), suggesting the neuroprotective effect of Rb1 in PD is due to its partial blockade of the loss of TH positive cells in the SNpc after MPTP treatment. Intriguingly, we found that 10 and 40 mg/kg Rb1 increased TH expression in the midbrain (p ¼ .005 and p ¼ .001, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 25.641, p ¼ .003; Supplementary Fig. 1D ). Additionally, subacute MPTP administration increased a-synuclein and GFAP expression in the SNpc, which is consistent with previous findings (Zhang et al., 2017a (Zhang et al., , 2017b Fig. 5A and B) . Furthermore, TUNEL staining indicated that Rb1 significantly prevents MPTPinduced nigral cell death in the SNpc (p ¼ .035 and p ¼ .008, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 27.806, p ¼ .004; Fig. 5C ). These results suggest that Rb1 attenuates movement disorder, prevents DA neuron death, and suppresses a-synuclein expression and astrogliosis. Our results confirm the neuroprotective effects of Rb1 in the MPTP mouse model of PD.
Ginsenoside Rb1 increases the expression and function of glutamate transporters and ameliorates glutamatergic pathway in the midbrain in the MPTP model of PD
Our findings suggest that Rb1 increases GLT-1 expression in the absence of MPTP treatment (Fig. 3) . As we have found that Rb1 attenuates movement disorder and prevents DA neuronal death in * represents a significant difference as compared with the control group.
MPTP-treated mice (Fig. 4) , we speculated that increased glutamate transporters may underlie the neuroprotective effects of Rb1 in the MPTP model. To assess this possibility, we examined glutamate transporter expression in MPTP-treated mice. Though Rb1 showed no obvious effects on GLT-1 and GLAST expression at the total level in MPTP-treated mice (Fig. 6A) Supplementary Fig. 2C ) which were reduced after MPTP administration. These results indicate that, by promoting glutamate transporter expression and function, Rb1 may prevent DA neuronal death and mitigate the excitotoxic damage to the nigrostriatal pathway caused by MPTP lesions. As glial glutamate transporters GLT-1 and GLAST are responsible for the majority of glutamate uptake in synaptic transmission , we further examined the effects of Rb1 on glutamate receptors and synaptic protein in the midbrain. At the total protein level, Rb1 increased the expression of N-methyl-Daspartate (NMDA) receptor subunit NR1 in MPTP-treated mice but showed no obvious effects on the expression of NR2B and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (A) Experimental timeline. Saline vehicle mice were intraperitoneally injected with vehicle (saline) once from day À3 to day 0 or day 6 to day 11, and twice from day 1 to day 5. MPTP mice were intraperitoneally injected with vehicle (saline) once from day À3 to day 0 or day 6 to day 11, and intraperitoneally injected with MPTP and saline from day 1 to day 5. Rb1 treatment mice were intraperitoneally injected with 10 or 40 mg/kg Rb1 once from day À3 to day 11, and intraperitoneally injected with MPTP from day 1 to day 5. All PD model animals were generated by administration of MPTP intraperitoneally for 5 consecutive days at a dose of 30 mg/kg free base (MPTP-HCl) in saline. The time interval between MPTP and Rb1 injections was more than 12 h (MPTP was given at 8:00 a.m. and Rb1 was given at 8:00 p.m.). One day after the last Rb1/saline injection, behavioral tests were performed and the animals were sacrificed by isoflurane anesthesia for tissue collection and electrophysiological recording. (BeD) Behavioral test results of 10 and 40 mg/kg Rb1 on the motor deficits in Pole-climbing test (B), Grasping test (C) and Rotarod test (D) in MPTP-treated mice (n ¼ 12e15 per group). (EeF) Immunohistochemistry of TH (E) and DAT (F) in the SNpc (n ¼ 6 per group). Scale bar, 100 mm. Results are expressed as the mean ± SEM, statistical significance was determined by one-way ANOVA and Bonferroni test as post-hoc comparisons.
* represents a significant difference as compared with the control group, subunit GluR1 (Fig. 6D) Fig. 6D ). Furthermore, MPTP treatment showed no obvious effects on the expression of presynaptic proteins synaptophysin (Fig. 6D) Fig. 6D ). To verify these findings, we examined the expression of NMDA and AMPA receptors at the membrane level. Our findings confirm that Rb1 prevents the MPTP-induced reduction of NR1 expression, and prevents MPTP-induced GluR2 expression (Fig. 6E) . These results suggest that the regulation of the glutamatergic transmission system may facilitate the amelioration of motor deficits by Rb1 and reduce DA neuronal loss in MPTP-lesioned mice.
Ginsenoside Rb1 increases the expression and function of glutamate transporters and ameliorates glutamatergic pathway in the prefrontal cortex in the MPTP model of PD
Previous studies have revealed that alterations of the glutamatergic system in the PFC may contribute to the behavioral changes during the progressive loss of nigrostriatal DA, and prefrontal cortex abnormalities may have a critical role in levodopainduced dyskinesias (Cerasa et al., 2013 (Cerasa et al., , 2015 Nakazato, 2002; Pflibsen et al., 2015) . Furthermore, cortico-nigral circuits play an important role in glutamate excitatory transmission (Kornhuber et al., 1984; Maurice et al., 1999) . Therefore, we examined the effects of Rb1 on the glutamate transporter expression pattern in the PFC in control and MPTP-treated mice. In control mice, intraperitoneal administration of 10, 20 and 40 mg/kg Rb1 increased GLT-1 expression in the PFC, while only 10 and 20 mg/kg Rb1 increased GLAST expression (GLT-1: p ¼ .006, p ¼ .002 and p ¼ .001, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 12 ¼ 2350.182, p ¼ .004; GLAST: p ¼ .002 and p ¼ .004, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 12 ¼ 53.518, p ¼ .001; Fig. 7A ). Furthermore, intraperitoneal administration of 40 mg/kg Rb1 promoted GLT-1 expression and reduced GLAST expression in a timedependent manner (Fig. 7B) . Intragastric administration of 40 mg/ kg Rb1 increased GLT-1 expression (p ¼ .013, Bonferroni post-hoc test; one-way ANOVA, F 3, 12 ¼ 61.662, p ¼ .038; Supplementary  Fig. 3A) , while intragastric administration of 20 mg/kg Rb1 decreased GLAST expression (p ¼ .008, Bonferroni post-hoc test; one-way ANOVA, F 3, 12 ¼ 102.205, p ¼ .002; Supplementary  Fig. 3A) . The increased GLT-1 expression following intragastric administration of 40 mg/kg Rb1 was observed at different time points and reached a peak at 24 h after administration, while 40 mg/kg Rb1 increased GLAST expression at 2 h and 24 h after administration (Bonferroni post-hoc test; one-way ANOVA, GLT-1: F 4, 15 ¼ 347.509, p ¼ .007; GLAST: F 4, 15 ¼ 47.082, p ¼ .004; Supplementary Fig. 3B ). These results suggest that Rb1 may induce glutamate transporter expression in the PFC in the absence of MPTP.
We next examined the effects of Rb1 on the expression of glutamate transporters, glutamate receptors, and pre-and postsynaptic proteins in the PFC in MPTP-treated mice. GLT-1 and GLAST expression was reduced in MPTP-treated mice, suggesting that glutamate uptake was diminished upon MPTP administration; however, Rb1 prevented the MPTP-induced reduction of GLT-1 and GLAST expression at the total protein level (GLT-1: p ¼ .015 and p ¼ .004, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 145.499, p ¼ .006; GLAST: p ¼ .002 and p ¼ .001, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 210.758, p ¼ .001; Fig. 7C ). In addition, 10 and 40 mg/kg Rb1 induced a significant upregulation of EAAC1 expression, suggesting that Rb1 may also play an antioxidative role in the PFC in MPTP-treated mice (p ¼ .000, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 108.113, p ¼ .000; Fig. 7C ). Being consistent with the regulatory pattern of Rb1 in the midbrain, 10 and 40 mg/kg Rb1 increased the expression of PSD-95 in MPTP-treated mice (p ¼ .003 and p ¼ .007, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 343.249, p ¼ .000; Fig. 7C ), demonstrating that Rb1 protects the postsynaptic proteins in the PFC. In addition, Rb1 prevented the MPTP-induced increase of NR2B expression, showing that 10 and 40 mg/kg Rb1 may attenuate NR2B-mediated glutamate excitotoxicity in the PFC in MPTP-treated mice (p ¼ .001 and p ¼ .004, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 127.974, p ¼ .000; Fig. 7C ). Unlike the case in the midbrain, in the PFC Rb1 prevented the MPTP-induced reduction of GluR2 expression, indicating that Rb1 may exert neuroprotective effects by elevating GluR2 expression in the PFC (p ¼ .024 and p ¼ .004, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 20 ¼ 80.365, p ¼ .000; Fig. 7C ).
To confirm the functional effects of increased glutamate transporter and receptor expression, we performed whole-cell patchclamp recording. We recorded the mEPSCs from PFC pyramidal neurons in the brain slices in each group. Here we found that MPTP increased the frequency of mEPSCs, which is suggestive of MPTPinduced excitotoxicity. However, MPTP showed no obvious effects on the amplitude of mEPSCs, suggesting MPTP may have no obvious effects on the glutamate binding to its postsynaptic receptors. Both 10 and 40 mg/kg Rb1 decreased the frequency of mEPSCs (p ¼ .034 and p ¼ .011, respectively, Bonferroni post-hoc test; one-way ANOVA, F 3, 46 ¼ 5.804, p ¼ .017; Fig. 8B ), which suggests that Rb1 inhibits glutamate release in the prefrontal cortical neurons in MPTP model mice. Moreover, Rb1 also showed no obvious effects on the amplitude of mEPSCs in MPTP model mice.
In addition, we found that 10 or 40 mg/kg Rb1 only treated group showed no obvious effects on the behavioral tests, glutamate receptors and synaptic protein expression in the midbrain and PFC in the normal C57BL/6 mice ( Supplementary Fig. 4 and 5) . We also found that Rb1 showed no obvious effects on the frequency and amplitude of mEPSCs from PFC pyramidal neurons in the normal mice brain slices ( Supplementary Fig. 6 ), suggesting Rb1 may have no obvious effects on the glutamate release and glutamate binding to its postsynaptic receptors in the normal mice.
Collectively these results indicate that Rb1 increases glutamate transporter expression in the midbrain and the PFC, and that the amelioration of motor deficits in MPTP model mice by Rb1 may be explained by improvements in the function of the glutamatergic system.
Discussion
The MPTP model of PD recapitulates several key features of PD pathology, including the degeneration of DA neurons, glutamate toxicity and glial activation (Blandini, 2010; Beal, 1998; Wang et al., 2009 ). Due to different experiment demands, three MPTP models (acute, sub-acute and chronic models) are commonly used. In this experiment, we used the sub-acute MPTP model, which is developed by Tatton and Kish (Tatton and Kish, 1997; Jackson-Lewis and Przedborski, 2007) , involving one injection of 30 mg/kg free base MPTP daily for five consecutive days. This MPTP regimen can cause apoptosis and depletes striatal dopamine by 40e50% in young adult C57BL/6 mice. Actually, the acute MPTP model can cause high rate of death (>20%), and according to our previous experience, the subacute MPTP model usually causes 10e15% of death rate (Zhang et al., 2017a (Zhang et al., , 2017b . In this work, we used nearly 146 mice for exploring the neuroprotective effects of Rb1 in MPTP mice model of * represents a significant difference as compared with the control group, ** p < .01, * p < .05. # represents a significant difference as compared with the MPTP group, ### p < .001, # p < .05. PD, and there are nearly 16 mice lost during MPTP experiments (the death rate is 9.8%). Remarkably, MPTP usually causes acute death of mice occurs within the first 24 h after the beginning of administration, we and others suggest these following several solutions may prevent the high rate of death upon MPTP treatment: ensure the gender and the strain of mice (C57BL/6 male mice); confirm the proper and safe practice of injection (usually performed by a certain person), ensure that the temperature in the procedure room (usually 25 C), confirm the time of drug administration with respect to MPTP regimen (we usually perform at 8:00 a.m.), and keep the mice warm after each MPTP administration.
As the main active ingredient of Panax ginseng, Ginsenoside Rb1 has been demonstrated to protect DA neurons, SH-SY5Y cells and PC12 cells from neurotoxicity (Ahmed et al., 2016; Gonzalez-Burgos et al., 2015; Radad et al., 2004) . Rb1 can also suppress the fibrillation and toxicity of a-synuclein and inhibit the polymerization of asynuclein in vitro (Ardah et al., 2015) . However, the neuroprotective role of Rb1 in a PD animal model and the underlying mechanism have not been well characterized. In this study, we provided evidence that Rb1 ameliorates the motor disorder in a PD animal model, and that these neuroprotective effects mainly involve the regulation of glutamate transporters. As the widely used traditional Chinese medicine, Ginseng is commonly administrated by oral in the clinical practice. In this experiment, we focus on the role of glutamate transporters in Parkinson's disease and we compared the effects of intraperitoneal and intragastrical administration of Ginsenoside Rb1 on the glutamate transporters expression. Notably, we found that intraperitoneal injection of Rb1 increased GLT-1 expression in midbrain and in prefrontal cortex, and we also found that Rb1-promoted glutamate transporters ameliorate motor deficits in PD animal models. Thus we conclude that intraperitoneal administration of Ginsenoside Rb1 may serve as a potential treatment in PD.
As the main excitatory neurotransmitter, glutamate regulates locomotor behavior, and in addition to dopaminergic neurons, Morales et al. have established the presence of glutamatergic neurons expressing vesicular glutamate transporter type 2 (VGluT2) mRNA in the substantia nigra compacta (SNC) and ventral tegmental area (VTA). Within the SNC, the neurons expressing VGluT2 were often found in the adjacent substantia nigra reticulata and substantia nigra pars lateralis (Yamaguchi et al., 2007 (Yamaguchi et al., , 2011 (Yamaguchi et al., , 2013 Nair-Roberts et al., 2008; Yamaguchi et al., 2013; Morales and Root, 2014) . These results suggest that some neurons in SNC have the ability to participate in glutamate signaling, and there are other glutamate inputs to the SNpc, including those from the subthalamic nucleus and the thalamus (Robledo and F eger, 1990) . Moreover, corticostriatal and thalamostriatal pathways are also involved in regulating the motor movement (Billet et al., 2012; Sohur et al., 2014; Parker et al., 2016) . Dysfunction of these pathways are associated with the motor deficits in PD (Antonelli et al., 2007; Blandini, 2010) .
Glutamate transporters are responsible for terminating glutamate excitatory transmission (Gerachshenko et al., 2009; Jensen et al., 2015; Zhang et al., 2016) , and previous studies have revealed that dysfunction of glutamate transporters contributes to motor deficits and that upregulation of glutamate transporters ameliorates the movement disorder in PD (Bacigaluppi et al., 2016; Leung et al., 2012; Zhang et al., 2017a Zhang et al., , 2017b . Using radioactive assays, we discovered that Ginsenoside Rb1 can promote astrogilal glutamate uptake. We then explored the effects of Rb1 on glutamate transporters in vitro and in vivo. Rb1 really increased the expression and function of GLT-1 in vitro in astrocytes and in vivo in the midbrain and PFC, and these mechanism may involve the nuclear translocation of NF-kB, which binds the EAAT2/GLT-1 promoter (Ghosh et al., 2011; Lee et al., 2008) . We also observed that Rb1 increased GLT-1 expression and function in MPP þ -treated astrocytes and in the midbrain, striatum and PFC in the MPTP mouse model of PD, suggesting that Rb1 promotes glutamate uptake and attenuates glutamate excitotoxicity in a PD model. Additionally, for the first time, we demonstrated that Rb1 prevents DA neuron death in the SNpc and striatum, and that Rb1 decreases a-synuclein expression and astrogliosis in the SNpc in the MPTP mouse model of PD. Thus we conclude that the amelioration of the motor function in MPTP mice model upon Rb1 treatment may involve in regulating the glutamatergic transmission in the VTA and SNpc, and may also involve in regulating the glutamatergic input from subthalamic nucleus and the thalamus to SNpc, and in addition, the glutamatergic input from the cortex and the thalamus to the striatum.
According to our TH immunohistochemistrical results, 10 mg/kg Rb1 showed no protective effects, however, the western blotting results and TUNEL results show that both 10 and 40 mg/kg doses of Rb1 are neuroprotective. We conclude that treatment with 40 mg/ kg Rb1 increases TH positive cells and TH expression, while treatment with 10 mg/kg Rb1 increases TH expression in MPTP mice model. In addition, the TUNEL assay also labels other cells except dopaminergic neuron. These results indicate that though 10 mg/kg dose of Rb1 did not increase TH positive cells, it increases TH expression in those cells that were still remaining after MPTP administration, besides, this dose of Rb1 may protects other neurons except TH cells. These combined effects may contribute to its benefit in the MPTP mice model.
As main sources of glutamate uptake, glutamate transporters play an important role in excitatory synaptic transmission . Because Rb1 increases glutamate transporter expression, we examined the effects of Rb1 on glutamate receptors and synaptic proteins. The abundance of NR1 (NMDA subunits) and GluR1 (AMPA subunits) in the cell plasma membrane has been reported to be decreased in PD animal models (Betarbet et al., 2004; Kaneda et al., 2005; Kong et al., 2009; Lai et al., 2003) . We also found that NR1 expression was decreased in the midbrain of MPTP-treated mice, and that Rb1 prevented the effects on NR1 expression, however, GluR1 expression showed no obvious changes in the total and membrane in midbrain. These results suggest that Rb1 may modulate the distribution of NMDA receptors (especially NR1) and prevent the overactivity of the nigrostriatal glutamatergic input that is generated by MPTP. Previous studies indicate that glutamate transporters prevent excessive activation of NMDA receptors and blockade of glutamate transporters resulted in an increased proportion of NR2B subunit activation (Nie and Weng, 2009 ). GLT-1 knockdown activates NMDA receptor (NR2B) and induces cell apoptosis, suggesting GLT-1 may modulate glutamatergic transmission via regulation of NMDA receptor (Gong et al., 2016) . Moreover, NR2B-containing NMDA receptors mediate glutamate excitotoxicity in neurodegenerative diseases, blocking the NR2B receptor thus attenuates glutamate excitotoxicity (Hammond et al., 2006; Liu et al., 2012a Liu et al., , 2012c . Conversely, Rb1 prevents the MPTPinduced increase of NR2B expression, suggesting that Rb1 may inhibit the glutamatergic excitotoxicity by regulating NR2B expression within the glutamate projection originates from the motor/sensory cortex to the SNpc (Watabe-Uchida et al., 2012).
GluR2 immunoreactivity was detected at presynaptic but not postsynaptic sites, suggesting that these receptors are likely to act by inhibiting glutamate release from presynaptic terminals rather than by modulating the postsynaptic glutamate-gated ion channels (Bradley et al., 2000) . Furthermore, activation of the GluR2 inhibits synaptic excitation and induces long-term depression of excitatory synaptic transmission in the SNpr (Bradley et al., 2000; Johnson et al., 2011; Poisik et al., 2005) . In this work, we observed different effects of Rb1 on GluR2 expression in the midbrain and in the PFC in MPTP-treated mice. Rb1 prevented the MPTP-induced increase of GluR2 expression in the midbrain, however it prevented the MPTP-induced decrease of GluR2 expression in the PFC. As GluR2 is located presynaptically and inhibits glutamate release, we conclude that adaptive upregulation of GluR2 in the midbrain in the MPTP mouse model of PD may compensate for increased glutamate, which is consistent with results from postmortem brain specimens of PD patients (Samadi et al., 2009 ). According to the electrophysiological results on the mEPSCs, glutamatergic transmission is increased in MPTP-treated mice, and MPTP-mediated reduction of GluR2 promotes glutamate release, while Rb1 decreases glutamate release and excitotoxicity by increasing GluR2 expression. Since glutamate transporter deficiency is reported to induce synaptic excitability and GLT-1 is capable of retaining the fast decay kinetics of EPSCs in Purkinje cells (Aida et al., 2015; Takatsuru et al., 2006) , we conclude that Rb1 promoting glutamate transporter expression contributes to its protection in the excitatory synaptic transmission in PD. Increasing evidence indicates that astrocytes play an important role in synapse formation and function, and a positive correlation between an increase in GLT-1 steady-state levels and synaptic protein PSD-95 was reported previously (Clarke and Barres, 2013; Zumkehr et al., 2015) . Here we also found that Rb1 significantly increased PSD-95 expression, suggesting Rb1 may protect postsynaptic neurons via promoting GLT-1 expression in midbrain and PFC in PD. Hence, we conclude that Rb1 may attenuate glutamate excitotoxicity and protect synaptic transmission via promoting glutamate transporter GLT-1 in PD.
In the past, Pflibsen et al. indicate that MPTP does not cause dopamine cell loss in the PFC, and they report that MPTP increases the VGluT1 expression in the PFC following DA loss (Pflibsen et al., 2015) , which further confirms our electrophysiological results about the increased glutamate release in the PFC (Fig. 8) . They also suggest that alterations in cortical glutamate nerve terminals (origin of VGluT1 protein) may contribute to the behavioral changes observed during the progressive loss of nigrostriatal DA in addition to the changes in corticostriatal (VGluT1) and thalamostriatal (VGluT2) input (Pflibsen et al., 2015) . However, because the major glutamate input to the cortex is either from the thalamus or from the contralateral cortex, besides the recurrent collaterals from adjacent pyramidal cells, thus we could not completely conclude that the increased glutamate release in the PFC is directly relevant to the dopamine cell loss in the SNpc. Considering Rb1 prevents the SNpc dopamine cell loss may due to its effects on the glutamate excitotoxicity, further electrophysiological studies in the midbrain need to be performed.
In this work, we found that Rb1 upregulates glutamate transporters GLT-1 in the midbrain and PFC in normal C57BL/6 mice, and Rb1 also upregulates glutamate transporter in MPTP mice model of PD. However, Rb1 showed no obvious effects on the behavioral tests, synaptic protein expression and synaptic glutamatergic transmission in the normal mice. As we know, in the normal condition glutamate transporters can quickly shape the dynamics of synaptically released glutamate (i.e. tonic glutamate), however, there are evidences that Rb1 can also control the extrasynaptic glutamate (i.e. ambient glutamate) levels (Jabaudon et al., 1999; Le Meur et al., 2007; Herman and Jahr et al., 2007; Sun et al., 2014) . Although Rb1 can upregulate glutamate transporter GLT-1 expression, it showed no obvious effects on the synaptic glutamatergic transmission in the normal C57BL/6 mice according to our electrophysiological results. These results suggest that, in the normal condition, Rb1 may upregulate GLT-1 expression to modulate the ambient glutamate levels, and this altered glutamate may be not affect the synaptic glutamatergic transmission. However, in the MPTP mice model of PD, on the one hand, Rb1 mainly upregulates GLT-1 expression to limit glutamate excitotoxicity, and on the other hand, Rb1 may inhibit glutamate release involving presynaptic mechanism via regulating GluR2 expression. Hence these two neuroprotective effects of Rb1 may be not linked. Thus we determine to show the results from Con, MPTP and MPTP þ Rb1 groups in the manuscript to underline the neuroprotective effects of Rb1 in the MPTP mice model of PD.
Because the glutamate excitotoxicity is an acute damage, we want to explore the role of glutamate transporters in this event. Thus in this work, the Rb1 administration was started 3 days before MPTP treatment, and it was continued throughout the development of MPTP lesion. Then, the GLT-1 overexpression was already maximal before MPTP was even started. Therefore, the used model in this work is completely a neuroprotective one, and the neurorestorative effects of Rb1 in PD animal models and its clinical significance in human PD patients need to be explored in the future.
Conclusions
Our present findings for the first time indicate the neuroprotective effects and underlying mechanism of Rb1 in treating the MPTP model of PD. Rb1 ameliorates motor deficits by regulating glutamate transporter expression and modulating the nigrostriatal and corticonigral glutamatergic transmission pathway. Collectively, these findings expand our knowledge about the protective mechanisms of Rb1 in PD animal model and provide evidence that Ginsenoside Rb1 may be a potential agent for the treatment of PD.
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